Wednesday, July 8, 2026

pharma · Analgesia · Postoperative Pain · HRTX

Heron Therapeutics

Heron Therapeutics is a pharma organization headquartered in Cary, USA. It trades on NYSE under ticker HRTX. Primary therapeutic focus areas include Analgesia, Postoperative Pain, Chemotherapy-induced Nausea and Vomiting

100 Regency Forest Dr, Cary, North Carolina 27518, US HQ
1983 Founded
188 Employees
Public company Type
HRTX · NYSE Ticker
Company details
Status
Public
HQ
100 Regency Forest Dr, Cary, North Carolina 27518, US
Founded
1983
Employees
188
Programs
18
Drugs
17
Patents
46
Clinical program

B10 L-BPA Injection

Phase 2 · small molecule · Malignant Brain Tumors

B10 L-BPA Injection for Malignant Brain Tumors is a Phase 2 program (small_molecule) at Heron Therapeutics with 1 ClinicalTrials.gov record(s).

← All Heron Therapeutics projects Phase 2 small molecule active

Internal code CMUH114-REC1-016

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Heron Therapeutics
Phase
Phase 2
Modality
small_molecule
Indication
Malignant Brain Tumors
Status
active
Trials
1